Phosphoethanolamine Residues on the Lipid A Moiety of Neisseria gonorrhoeae Lipooligosaccharide Modulate Binding of Complement Inhibitors and Resistance to Complement Killing

Lisa A. Lewis, University of Massachusetts
William Shafer, Emory University
Tathagat Dutta Ray, New York University
Sanjay Ram, University of Massachusetts
Peter A. Rice, University of Massachusetts

Journal Title: Infection and Immunity
Volume: Volume 81, Number 1
Publisher: American Society for Microbiology | 2013-01, Pages 33-42
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1128/IAI.00751-12
Permanent URL: https://pid.emory.edu/ark:/25593/s529k

Final published version: http://dx.doi.org/10.1128/IAI.00751-12

Copyright information:
© 2013, American Society for Microbiology. All Rights Reserved.

Accessed December 29, 2019 12:49 AM EST
Phosphoethanolamine Residues on the Lipid A Moiety of *Neisseria gonorrhoeae* Lipooligosaccharide Modulate Binding of Complement Inhibitors and Resistance to Complement Killing

Lisa A. Lewis, William M. Shafer, Tathagat Dutta Ray, Sanjay Ram, Peter A. Rice

Department of Medicine, Division of Infectious Diseases and Immunology, University of Massachusetts School of Medicine, Worcester, Massachusetts, USA; Laboratories of Bacterial Pathogenesis, Medical Research Service, Veterans Affairs Medical Center (Atlanta), Decatur, Georgia, USA; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, USA; Department of Medicine, New York University School of Medicine, New York, New York, USA

Loss of phosphoethanolamine (PEA) from the lipid A of gonococcal strain FA19 results in increased sensitivity to killing by the classical pathway of complement. Here we demonstrate that loss of PEA from lipid A diminishes binding of the complement regulatory protein C4b binding protein (C4BP) to the FA19 porin B (PorB), providing a molecular basis to explain the susceptibility of an *lptA* null strain of FA19 to killing by normal human serum (NHS). Loss of PEA from lipid A in three additional gonococcal strains that expressed diverse PorB molecules also resulted in decreased C4BP binding, increased deposition of C4b, and increased susceptibility to killing by NHS. Complementation of *lptA* null strains with *lptA* restored C4BP binding, decreased C4b deposition, and increased resistance to killing by NHS. These effects of lipid A PEA on C4BP binding to gonococcal PorB and serum resistance were simulated when gonococcal PorB was expressed in a meningococcal background. Loss of PEA from lipid A also affected binding of the alternative pathway regulator factor H (fH) to PorB of some strains. For instance, PorB molecules of *lptA* null mutants of strains 252 and 1291 bound less fH than those of their parent strains when lipooligosaccharide (LOS) was sialylated, whereas PorB molecules of *lptA* null mutants of strains FA1090 and 273 retained the ability to bind fH when LOS was sialylated. These data indicate that replacement of lipid A with PEA alters binding of C4BP and fH to PorB and contributes to the ability of gonococci to resist complement-mediated killing.

*N. gonorrhoeae* causes 106 million of the estimated 498 million new cases of curable sexually transmitted infections that occur globally every year (1). Antimicrobial therapy is a key element of effective management of gonorrhoea, but in the future, drug resistance may compromise the ability to adequately limit infection. *N. gonorrhoeae* strains that are resistant to multiple classes of antimicrobial drugs, including β-lactams, tetracyclines, and fluoroquinolones, have been well described (2, 3). The recent isolation of ceftriaxone-resistant strains of *N. gonorrhoeae* in Japan and Europe (4–6) threatens the use of this antimicrobial agent, which has been recommended as first-line treatment by the U.S. Centers for Disease Control and Prevention since 1993 (7). High infection rates coupled with the increasing presence of multidrug-resistant strains could transform this once treatable infection into a global health problem of epic proportions. To cause infection, gonococci must evade host immune defenses and avoid complement-mediated killing. Activation of the complement system directly facilitates bacterial killing by promoting formation of the membrane attack complex and by enhancing opsonophagocytosis. Antibody (Ab)-dependent classical pathway activation is essential to initiate direct complement-dependent killing of gonococci (8, 9). To thwart the immune response in humans, gonococci highjack host complement-inhibitory proteins that normally function to downregulate complement activation; gonococci use these proteins to inactivate complement on their surfaces. The host uses fluid-phase complement regulators to keep complement activation to a minimum under normal physiological conditions, thereby avoiding inadvertent damage to self-tissues. Factor H (fH) and C4b binding protein (C4BP) are two key fluid-phase regulators that control the alternative and classical pathways of complement, respectively. These proteins function to accelerate the decay of C3 convertases in their respective pathways and act in conjunction with factor I to convert either hemolytically active C3b to the inactive iC3b fragment (fH; alternative pathway) or active C4b to inactive C4d (C4BP; classical pathway).

Gonococcal strains vary in the ability to resist killing by normal human serum (NHS); resistance to killing by NHS can be classified as either unstable or stable. Unstable serum resistance is dependent upon growth of the organism in the presence of CMP-N-acetylenuraminic acid (CMP-NANA), simulating what occurs in vivo (10–13). In this case, sialic acid links to terminal lacto-N-neotetraose (LNT) on gonococcal lipooligosaccharide (LOS) and facilitates fH binding to the gonococcal porin B (PorB) molecule (14). Stable serum resistance is independent of growth conditions, and gonococcal strains that exhibit stable serum resistance either bind fH in the absence of LOS sialylation or bind C4bp directly to their PorB molecules (15–17). Previously, we characterized the interactions between C4BP and gonococcal PorB (15) and demonstrated that entirely truncating HepI substitutions on gonococ-
cal LOS markedly decreased C4BP binding to certain PorB.1B-bearing gonococcal strains (such as MS1 and 1291) but did not affect binding of C4BP to PorB.1A-bearing strains, such as FA19 (18). Inhibition of C4BP binding to gonococcal LOS of stably serum-resistant gonococci results in serum sensitivity (16). Together, these observations highlight the complex relationship between LOS structure and binding of complement regulators to gonococcal porins.

The lipid A structure of neisserial LOS consists of a phosphorylated diglucosamine:phosphoethanolamine (PEA) moiety that may be used as substitutions at both the 1 and 4’-positions of lipid A (19). Modification of lipid A with phosphoryl substitutions generally results in pleiotropic biological effects. Phosphoryl substitution on neisserial lipid A confers activation of NF-κB through Toll-like receptor (TLR) signaling, highlighting the potential for lipid A variation to differentially activate the innate immune system (20). PEA residues on lipid A have specifically been implicated in neisserial pathogenesis (19, 21, 22). PEA substitutions on Neisseria meningitidis lipid A are important for binding of meningococci to endothelial and epithelial cells and in resistance of meningococci to polymyxin B and host-derived cationic antimicrobial peptides such as LL-37 (21, 23). Loss of PEA from the lipid A of gonococcal strain FA19 increased sensitivity to polymyxin B and LL-37 and dramatically decreased resistance of strain FA19 to killing by NHS (22), a phenotype that was not shared by N. meningitidis lacking lipid A PEA (21). In this study, we sought to identify the underlying mechanisms responsible for serum sensitivity of gonococcal strains lacking lipid A PEA.

**MATERIALS AND METHODS**

**Bacterial strains and growth conditions.** N. gonorrhoeae strains FA19 (24), 252 (17), 273 (17), FA1090 (25), and 1291 (26) and N. meningitidis strains H44/76 (27) and Y2220 (28) have been described previously. The construction and characterization of the following mutant strains have been described elsewhere, as indicated: FA19 lptA::spc (22), FA19 lptA::spc lptA+ (22), H44/76 siaD::cat siaD::cat siaD::ermC (29), H44/76 cap fluoride (H44/76 siaD::cat fHbp::erm) (29), Y2220 cap− lptA+ (Y2220 siaD::cat siaD::cat::kan) (30), Y2220 cap− lptA− (Y2220 siaD::cat siaD::cat::kan) as previously described (31). Relevant genotypic and phenotypic information is listed in Table 1.

Neisserial strains were routinely cultured on chocolate agar plates supplemented with IsoVitaleX equivalent at 37°C in an atmosphere of 5% (vol/vol) carbon dioxide. To sialect the LOS, bacteria were cultured onto chocolate agar plates supplemented with 100 μg/ml CAMP-NANA (0.15 mM), isopropl-β-D-thiogalactopyranoside (IPTG; 1 mM) was used to induce expression of lptA from the IPTG-inducible promoter in strain FA19 lptA::spc lptA+. GC plates supplemented with IsoVitaleX equivalent were used for antibiotic selection. Antibiotics were used when indicated, at the following concentrations: kanamycin, 100 μg/ml; chloramphenicol, 7 μg/ml; erythromycin, 5 μg/ml; spectinomycin, 50 μg/ml; and polymyxin B, 100 μg/ml or 2 μg/ml Listeria monocytogenes (Invitrogen, Carlsbad, CA) were routinely cultured in Luria-Bertani (LB) broth or on LB agar. Antibiotics were used as needed, at the following concentrations: kanamycin, 50 μg/ml; ampicillin, 125 μg/ml; chloramphenicol, 50 μg/ml; erythromycin, 400 μg/ml; and spectinomycin, 100 μg/ml.

**Sera.** NHS collected from healthy human volunteers without a history of neisserial disease and who had not received any meningococcal vaccine and were not under antibiotic treatment were pooled, aliquoted, and stored at −80°C until used. Hemolytic activity of the serum pool was confirmed using the Total Haemolytic Complement assay (Binding Site, Birmingham, United Kingdom).

**Construction of lptA mutant strains.** Mutations in lptA were constructed (in strains 252, 272, FA1090, 1291, H44/76 cap−, H44/76 cap fHbp, Y2220 cap− lptA−, and Y2220 cap− lptA− PorFA19) as previously described for FA19 lptA::spc (22). In brief, lptA::spc was amplified by PCR from chromosomal DNA prepared from strain FA19 lptA::spc, using primers lptA1R (GGCGGTGCTTCTACAGAAAT) and lptA2F (TCGGGTGGTT

**TABLE 1** Bacterial strains and their relevant characteristics

<table>
<thead>
<tr>
<th>Strain</th>
<th>Relevant characteristics</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>N. gonorrhoeae strains</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FA19 lptA::spc</td>
<td>PorB.1A (serotype PIA-1), L8 LOS, binds C4BP, binds fH</td>
<td>24</td>
</tr>
<tr>
<td>FA19 lptA::spc lptA+</td>
<td>PorB.1A, L8 LOS; lptA::spc lptA+ (FA19 lptA::spc complemented with lptA driven from an IPTG-inducible promoter)</td>
<td>22</td>
</tr>
<tr>
<td>273 PorB.1A (serotype PIA-6), LNT (3F11) LOS, binds C4BP, binds fH</td>
<td>17</td>
<td></td>
</tr>
<tr>
<td>273 lptA::spc</td>
<td>PorB.1A, LNT (3F11) LOS; lptA::spc</td>
<td>This work</td>
</tr>
<tr>
<td>252 PorB.1A (serotype PIA-4), LNT (3F11) LOS, does not bind C4BP, binds fH</td>
<td>17</td>
<td></td>
</tr>
<tr>
<td>252 lptA::spc</td>
<td>PorB.1A, LNT (3F11) LOS; lptA::spc</td>
<td>This work</td>
</tr>
<tr>
<td>FA1090 PorB.1B (serotype PIB-3*), LNT (3F11) LOS, binds C4BP, binds fH</td>
<td>25</td>
<td></td>
</tr>
<tr>
<td>FA1090 lptA::spc</td>
<td>PorB.1B, LNT (3F11) LOS; lptA::spc</td>
<td>This work</td>
</tr>
<tr>
<td>1291 PorB.1B (serotype PIB-3*), LNT (3F11) LOS, binds C4BP, binds fH</td>
<td>26</td>
<td></td>
</tr>
<tr>
<td>1291 lptA::spc</td>
<td>PorB.1B, LNT (3F11) LOS; lptA::spc</td>
<td>This work</td>
</tr>
<tr>
<td>N. meningitidis strains</td>
<td></td>
<td></td>
</tr>
<tr>
<td>H44/76 cap−</td>
<td>Unencapsulated; siaD::cat</td>
<td>29</td>
</tr>
<tr>
<td>H44/76 cap− fHbp</td>
<td>Unencapsulated; siaD::cat fHbp::ermC</td>
<td>29</td>
</tr>
<tr>
<td>H44/76 cap− lptA::spc</td>
<td>Unencapsulated; siaD::cat lptA::spc</td>
<td>This work</td>
</tr>
<tr>
<td>H44/76 cap− fHbp lptA::spc</td>
<td>Unencapsulated; carries insertion inactivation of LOS sialeytransferase; siaD::cat lptA::spc</td>
<td>This work</td>
</tr>
<tr>
<td>Y2220 cap− lst</td>
<td>Unencapsulated, carries insertion inactivation of LOS sialeytransferase; siaD::cat lptA::spc</td>
<td>This work</td>
</tr>
<tr>
<td>Y2220 cap− lst lptA::spc</td>
<td>Unencapsulated, carries insertion inactivation of LOS sialeytransferase; siaD::cat lptA::spc</td>
<td>This work</td>
</tr>
<tr>
<td>Y2220 cap− lst PorFA19 lptA::spc</td>
<td>Unencapsulated, carries insertion inactivation of LOS sialeytransferase, has Y2220 PorB2 replaced with FA19 PorB.1A, binds C4BP and fH; siaD::cat lptA::spc lptA+</td>
<td>This work</td>
</tr>
</tbody>
</table>

* The FA1090 and 1291 PorB molecules are 97% identical, with 11 amino acid differences in 348 amino acids.
TGGCACACATAT), and the resulting 3.4-kb amplicon was cloned into the vector pCR2.1 Topo (Invitrogen). The resultant plasmid was linearized with SacI and used to transform neisserial strains as described previously (32). Transformants were selected on GC agar plates containing 50 μg/ml spectinomycin. Proper insertion of the spectinocycin resistance cassette in lptA was confirmed by PCR using primers LptAIR and LptA2F. We demonstrated previously that mutations in LptA increase sensitivity to the antibiotic polymyxin B (22). All wild-type strains grew on GC agar plates supplemented with 100 μg/ml polymyxin B. The LptA mutants were found to be fully sensitive to 2 μg/ml polymyxin B.

**Complement component and C4BP deposition.** Western blotting was used to localize C4-target complexes and was carried out as described previously (33). Briefly, 3 × 10^8 CFU of bacteria, suspended in Hanks balanced salt solution containing 0.15 mM CaCl_2 and 1 mM MgCl_2 (HBSS^- ), were incubated for 30 min at 37°C with NHS (at the concentration specified for each experiment) in a final reaction volume of 500 μl. Bacteria were washed twice with 500 μl HBSS^- and suspended in the same buffer. Samples were solubilized with lithium dodecyl sulfate sample buffer (NuPAGE LDS sample buffer; Invitrogen) containing 2-mercaptoethanol (2.5% final concentration) at 37°C for 30 min. Proteins were separated in NuPAGE Novex 4 to 12% Bis-Tris gradient gels by use of NuPAGE 3-morpholinopropanesulfonic acid (MOPS) running buffer and then were transferred to polyvinylidene difluoride (PVDF) membranes (34). To verify equal loading across lanes, membranes were cut horizontally at the level of the ~50-kDa marker prior to the blocking step. The portion of the membrane containing proteins migrating faster than ~50 kDa was separately stained with Coomassie blue (Imperial protein stain kit; Pierce). The location of C4b was defined by Western blotting. Bacteria from an overnight culture on chocolate agar plates were inoculated onto fresh chocolate agar and grown for 6 h at 37°C in 5% CO_2. Bacteria were washed twice with 500 μl HBSS^- and suspended in the same buffer. Samples were solubilized with lithium dodecyl sulfate sample buffer (NuPAGE LDS sample buffer; Invitrogen) containing 2-mercaptoethanol (2.5% final concentration) at 37°C for 30 min. Proteins were separated in NuPAGE Novex 4 to 12% Bis-Tris gradient gels by use of NuPAGE 3-morpholinopropanesulfonic acid (MOPS) running buffer and then were transferred to polyvinylidene difluoride (PVDF) membranes (34). To verify equal loading across lanes, membranes were cut horizontally at the level of the ~50-kDa marker prior to the blocking step. The portion of the membrane containing proteins migrating faster than ~50 kDa was separately stained with Coomassie blue (Imperial protein stain kit; Pierce). The location of C4b was defined by Western blotting. Bacteria from an overnight culture on chocolate agar plates were inoculated onto fresh chocolate agar and grown for 6 h at 37°C in 5% CO_2. Bacteria were suspended to a final concentration of 3 × 10^8 CFU/ml in HBSS^- in 300 μl (~10^8 organisms) and then centrifuged and incubated with FH purified from human plasma (Complement Technology, Inc.) at the concentration specified for each experiment. Bound FH was detected using the anti-FH MAb 90X (Quadel). Fluorescein isothiocyanate (FITC)-conjugated anti-mouse IgG (Sigma) was used as the secondary antibody. All reaction mixtures were made in HBSS^-1% bovine serum albumin (BSA) in a final volume of 100 μl. Flow cytometry was performed using either a FACSCalibur (Becton, Dickinson) or LSR II (Becton, Dickinson) instrument, and data analysis was performed using the FlowJo data analysis software package (TreeStar).

C4BP binding to bacteria was detected by fluorescence-activated cell sorting (FACS) using methods similar to those described above for FH. Bacteria were incubated in 2% to 20% NHS, as indicated in each experiment (as a source of C4BP), and bound C4BP was detected using either sheep polyclonal (1:100 dilution) anti-C4BP (Biodesign International) or anti-C4BP MAb 67 (a kind gift from Anna M. Blom, Lund University, Sweden) (36). Bound antibody was disclosed with donkey anti-sheep IgG-FITC (Sigma).

**Bacterial killing by NHS.** Susceptibility of neisserial strains to complement-mediated killing was determined using a serum bactericidal assay as described previously (37). Bacteria from overnight cultures on chocolate agar plates were inoculated onto fresh chocolate agar and grown for ~6 h at 37°C in 5% CO_2. For experiments that required sialylation of LOS, bacteria were cultured onto fresh chocolate agar plates supplemented with 100 μg/ml CMP-NANA. Brieﬂy, 2,000 CFU of bacteria was incubated with serum (at the concentration specified for each experiment) in a final reaction volume of 150 μl. Aliquots of 25 μl were plated in duplicate at the start of the assay (t0) and after incubating the reaction mixture at 37°C for 30 min (t30). Survival was calculated as the number of viable colonies at t30 relative to baseline colony counts at t0. Each experiment was repeated at least three times, and the mean ± range survival was calculated from at least three independently performed experiments.

**SDS-PAGE and Western blotting for LOS characterization.** The LNT epitope of neisserial LOS becomes sialylated when the organism is grown in medium supplemented with CMP-NANA. MAb 3F11 recognizes the LNT epitope, and a loss of 3F11 reactivity has been used to monitor sialylation of LOS (39). We examined LOSs of all strains by silver staining and checked for expression of the LNT epitope by Western blotting with MAb 3F11 and bacteria grown in the presence or absence of CMP-NANA. In brief, bacteria were suspended in NuPAGE LDS sample buffer (Invitrogen) and digested with proteinase K (Sigma) for 1 h at 55°C, and resolved in 12% Bis-Tris NuPAGE gels (Invitrogen) by use of morpholinethanesulfonic acid (MES) running buffer (Invitrogen). LOS was visualized by staining with silver (Bio-Rad Laboratories, Hercules, CA). For Western blotting, LOS was transferred to PVDF membranes (Millipore), and the membranes were probed with tissue culture supernatants containing MAb 3F11. Bound 3F11 was detected with alkaline phosphatase-conjugated goat anti-mouse IgM (Sigma).

**RESULTS**

Lipid A PEA limits classical pathway activation on N. gonorrhoeae. Activation of the classical pathway results in covalent binding of the 87-kDa C4bα’ fragment of C4 to target molecules on the bacterial cell surface. Gonococcal LOS, the opacity (Opa) proteins, and PorB are targets for C4b; these C4bα’-target complexes migrate with calculated masses of ~90 kDa, ~100 kDa, and ~130 kDa, respectively (33). To better understand the mechanism underlying the serum-sensitive phenotype of LptA mutants, initially we compared the deposition of C4b on strains FA19 (serum resistant), FA19 lptA::spc, and FA19 lptA::spc complemented with wild-type lptA under the control of an IPTG-inducible lac promoter (FA19 lptA::spc lptA^+), using 50% NHS for Western blotting (Fig. 1). Construction and characterization of these strains have been described previously (22). Binding of C4bα’ fragments was readily apparent on gonococcal LOS, Opa, and porin for FA19 lptA::spc (Fig. 1). C4bα’-target complexes were less apparent on...
the serum-resistant wild-type FA19 strain than on FA19 lpta::spc. This result is consistent with the serum-sensitive phenotype of FA19 lpta::spc. Complementation of FA19 lpta::spc with wild-type lpta restores serum resistance (22). Consistent with this result, complementation also resulted in a decrease in C4b deposition (Fig. 1, FA19 lpta::spc lpta<sup>+</sup> IPTG). None of the anti-C4-reactive bands was detected in control samples lacking NHS (data not shown). These data indicate that in the absence of lipid A PEA, gonococci regulate the classical pathway less effectively, as reflected by the higher levels of C4b detected.

**Lipid A PEA expression is required for maximal C4BP binding to N. gonorrhoeae.** Decreased C4b detected on wild-type FA19 may have resulted from fewer C4b molecules having been deposited initially on the organism, for example, because of less IgG and/or IgM binding. We did not detect differences in IgG or IgM binding to these strains by FACS (data not shown), which suggested that processing of C4b was impaired on the mutant strain rather than diminished deposition of C4b on wild-type bacteria at the outset.

*N. gonorrhoeae* strain FA19 was isolated from the cervix of a patient with disseminated gonorrhea and is stably serum resistant (24, 40). PorB on FA19 binds the complement regulatory protein C4BP (16), and bound C4BP serves as a cofactor in the factor C4BP MAb 104) results in killing by NHS (16). C4BP binding to PorB on FA19 is important for maximal binding of C4BP to FA19 PorB; strains that bind C4BP to strain FA19 lpta::spc was assessed by FACS analysis. Bacteria were incubated in 20% NHS (~40 µg/ml C4BP) for 30 min at 37°C, and bound C4BP was detected using sheep anti-human C4BP Ab followed by anti-sheep IgG–FITC. Median fluorescence values for a typical experiment are shown to the right. Data from one experiment of at least three independent experiments are shown.

**C4BP binding to PorB.1A and PorB.1B strains and influence of lipid A PEA.** We next sought to investigate the role of lipid A PEA in C4BP binding to other PorB.1A and PorB.1B strains (16). We constructed lpta<sup>+</sup> mutations in the following strains that bind C4BP, measured the mutant strains’ ability to bind C4BP, and compared complement killing with that of the parent strains.
Wild-type gonococcal strains 273 (PorB.1A), FA1090 (PorB.1B), and 1291 (PorB.1B) each bound more C4BP than the corresponding lptA mutant (Fig. 3A and B); strains 273 and FA1090 were fully resistant to killing by 10% NHS (Fig. 3C) and bound more C4BP than strain 1291 (Fig. 3A), which was less resistant (Fig. 3B). These data indicated that PEA substitution of lipid A, required for maximal binding of C4BP to PorB, was generalizable to diverse gonococcal PorB molecules that bound C4BP.

Lipid A PEA contributes to serum resistance by modulating fH binding. Some gonococcal strains possess PorB molecules that do not bind C4BP, yet these strains are serum resistant (14, 16). We explored the role of lipid A PEA in serum resistance of one such strain, strain 252 (17), by constructing an lptA::spc mutation and comparing the mutant’s ability to resist killing by NHS with that of the wild type. Interestingly, 252 lptA::spc was killed more readily than the parent strain by NHS, with 0% survival compared to 92% survival in 10% NHS (Fig. 4A). Lack of C4BP binding to wild-type 252 was confirmed as reported previously (16). As expected, 252 lptA::spc did not bind C4BP, either by Western blot assay (data not shown) or by FACS (Fig. 4B). This indicates that a separate mechanism exists to mediate lipid A PEA-enhanced serum resistance of strain 252.

While the PorB of strain 252 (PorB.1A) does not bind C4BP, it does bind the soluble alternative pathway regulatory protein fH in the absence of LOS sialylation (14, 17). We compared fH binding to strains 252 and 252 lptA::spc by FACS. As expected, wild-type 252 bound fH (14, 41), but the lptA::spc mutant of 252 did not (Fig. 4C). Loss of the ability to bind fH in the 252 lptA::spc mutant likely accounts for its sensitivity to killing by NHS.

The observation that lipid A PEA modulates fH binding to strain 252 raised the possibility that lipid A PEA may play a broader role in binding of complement-inhibitory proteins to the surfaces of gonococci. Sialylation of LNT-expressing LOS that occurs in vivo also enhances fH binding to gonococci to promote resistance to killing by NHS (14), and we sought to examine the role of lipid A PEA upon binding of fH to sialylated gonococci that otherwise bind fH minimally in the unsialylated state. All strains were confirmed to express the LNT epitope in the absence of CMP-NANA by their ability to react with MAb 3F11. Sialylation was confirmed by a loss of 3F11 reactivity on Western blots (data not shown). As shown in Fig. 5A, all wild-type strains bound fH following growth in CMP-NANA. With the exception of 252, which binds fH even in the unsialylated state, binding of fH to the other unsialylated gonococcal strains was similar to that of the isotype controls (data not shown). The effect of lipid A PEA on fH binding to sialylated FA1090 and 273 was not (or minimally) reduced by loss of lipid A PEA, while fH binding to sialylated strain 1291 was abrogated in the lptA::spc mutant. Loss of lipid A PEA also reduced
FIG 4 Role of gonococcal lipid A PEA in susceptibility to killing by NHS and binding of complement regulators. (A) Percent survival of gonococcal strains 252 and 252 lptA::spc in 10% NHS. Values represent the mean (± range) survival calculated from three or more separately performed experiments. (B) C4BP binding to strains 252 and 252 lptA::spc. Bacteria were incubated in 20% NHS (−0 μg/ml C4BP) for 30 min at 37°C; bound C4BP was detected by FACS analysis using sheep anti-human C4BP antibody and anti-sheep IgG–FITC. C4BP binding to gonococcal strain 273 is shown as a positive control. A representative (negative) control where NHS (C4BP) was omitted from the reaction mixture is also shown (shaded gray). Median fluorescence values for a typical experiment are shown to the right. Each experiment was repeated at least three times. (C) fH binding to strains 252 and 252 lptA::spc. Gonococcal strains were incubated with purified human fH (5 μg/ml), and bound fH was detected by FACS analysis using anti-fH MAb 90X (Quidel) and anti-mouse IgG–FITC. A representative negative control where purified human fH was omitted from the reaction mixture is shown (shaded gray). Median fluorescence values for a typical experiment are shown to the right. Each experiment was repeated at least three times.

binding of fH to sialylated 252, although to a lesser extent than in sialylated strain 1291 lptA::spc.

N. gonorrhoeae strains FA19 (22), 273, FA1090 (Fig. 3C), and 252 (Fig. 4A) fully resisted killing by NHS, while the ability of strain 1291 to resist killing was “intermediate” (Fig. 3C). lptA mutants of all of these unsialylated strains were fully killed by NHS (22) (Fig. 3C and 4A). Upon LOS sialylation, the ability of lptA mutant strains to bind fH was variable. To determine if fH binding correlated with serum resistance of sialylated lptA::spc mutants, we performed serum killing assays on organisms grown in the presence and absence of CMP-NANA (Fig. 5B) to sialylate LOS. The FA19 wild type did not express LNT LOS (data not shown) and was not tested. As predicted, sialylation of LOS did not increase the survival of mutant strains 1291 lptA::spc and 252 lptA::spc, which had already showed impaired fH binding resulting from the lptA mutation (Fig. 5A). Although binding of factor H in both 273 lptA::spc and FA1090 lptA::spc was maintained and not enhanced upon LOS sialylation (Fig. 5A), sialylation of LOS did increase survival in strain 273 lptA::spc but not strain FA1090. Sialylated FA1090 lptA::spc remained sensitive to killing by NHS, despite fH binding. Overall, these data indicate that the role of lipid A PEA in modulating binding of fH and resistance to killing by NHS of sialylated gonococci is strain specific.

Confirmation of the role of lipid A PEA in gonococcal serum resistance in a heterologous background. Meningococci do not bind significant amounts of C4BP in the presence of isotonic buffers (42), and unlike those of gonococci, meningococcal porin molecules have not been reported to contribute to binding of fH to intact bacteria as detected by FACS assays (29, 37, 43). Meningococci bind to fH via two surface proteins, fH binding protein (fHbp) and neisserial surface protein A (NspA) (29, 37). Loss of lipid A PEA in N. meningitidis resulted in increased sensitivity to polymyxin B but did not increase sensitivity to NHS (21). The effects of losing lipid A PEA were further examined in N. meningitidis, first in an unencapsulated (cap−) N. meningitidis strain and then in a cap− N. meningitidis strain genetically modified to express N. gonorrhoeae PorB.

FIG 5 Factor H binding and serum resistance of sialylated gonococci that lack lipid A PEA. (A) Factor H binding to sialylated gonococci and their lptA mutants that lacked lipid A PEA. Gonococcal strains were grown in the presence of CMP-NANA (0.15 mM) and then incubated with purified human fH (5 μg/ml), and bound fH was detected by FACS analysis using anti-fH MAb 90X (Quidel) and anti-mouse IgG–FITC. Data for wild-type strains are shaded black, and those for the corresponding isogenic lptA mutant strains lacking lipid A PEA are outlined in gray. A representative control where purified human fH was omitted from the reaction mixture is shown at the top (shaded gray) and at the bottom (shaded gray). Median fluorescence values for a typical experiment are shown to the right. Each experiment was repeated at least three times. (B) Percent survival of gonococcal strains FA1090, 1291, 252, and 273 and their lptA::spc mutants in 10% NHS. Gonococcal strains were grown in the presence of CMP-NANA (0.15 mM) to sialylate the LOS where indicated (LOS sia; shaded gray). Values represent the mean (± range) survival calculated from three or more separately performed experiments.
Lipid A PEA Alters Complement Inhibitor Binding

Neisserial LOS exhibits a wide range of structural variation, and the composition of the LOS outer core influences binding of complement-regulatory proteins, such as fH and C4BP, to gonococcal porin. Here we report that variations in PE content of the lipid A moiety of gonococcal LOS also influence binding of the complement inhibitors C4BP and fH to gonococcal PorB. To our knowledge, this is the first report of modulation of complement regulator binding to microbes by lipid A PEA substitutions. A summary of how neisserial surface structures modulate complement activation and inhibition is provided in Table S1 in the supplemental material.

Loss of PEA residues from the lipid A of gonococcal strain FA19 results in increased killing of the organism by the classical pathway of NHS. We provided a molecular basis for the extreme susceptibility of FA19 lptA::spc to killing by NHS by demonstrating that a loss of PEA from lipid A diminishes binding of C4BP to gonococcal PorB. Additional gonococcal strains that bind C4BP were tested, and in all cases, the loss of PEA from the lipid A resulted in a dramatic decrease in C4BP binding compared to the wild-type parent. Loss of C4BP binding, as previously described (16), was associated with an increase in deposition of C4b and susceptibility to killing by NHS in the absence of LOS sialylation. Despite larger amounts of C4b deposited on their surfaces (Fig. 1), gonococcal mutant strains lacking lipid A PEA bound less C4BP (Fig. 2B), which suggested that C4BP bound to bacteria did not occur through C4b deposited on the bacterial surface. Binding of purified C4BP parallels binding of C4BP in the context of NHS and is inversely proportional to C4b deposited on the bacteria (16), lending strong support to the fact that C4BP bound to bacteria in the context of NHS does not occur through C4b. Complementation studies further demonstrated that restoration of PE to the lipid A of the FA19 mutant restored C4BP binding, decreased C4b deposition, and increased resistance to killing by NHS.

Loss of PEA from lipid A affected binding of fH to some gonococcal PorB molecules but not others; this effect did not correlate with a specific porin type (not specific to either PorB.1A or PorB.1B). fH binding to the PorB molecules of strains 252 and 1291 was impaired by the loss of lipid A PEA, even in the presence of LOS sialylation. However, the PorB molecules of strains FA1090 and 273 retained the ability to bind fH in the absence of lipid A PEA when their LOS was modified with sialic acid. Wild-type gonococcal strains vary widely in the ability to bind C4BP and/or fH. Gonococcal porins range in size from 34 to 37 kDa and possess eight antigenically variable surface loops. While the N-terminal loop of PorB.1A on select strains appears to be necessary for C4BP binding, loops 5 to 7 of PorB.1B on some strains may contain the binding site for C4BP (16). Variations in PorB binding to fH are also common. Most gonococci require LOS sialylation for maximal interaction of fH with PorB; however, the PorB molecules from certain strains, such as 252 and 15253, bind fH well in the absence of LOS sialylation (17, 41). In addition, subtle differences in the PorB amino acid sequence may explain the differential effects of lipid A PEA on fH binding to sialylated gonococci. For example, a linear peptide that represents FA19 loop 5 blocks fH binding to the homologous strain but not to heterologous strains with distinct loop 5 sequences (17). Diversity in PorB sequences, differences in the presentation of PorB on the surface of

FIG 6 Lipid A PEA does not affect fH binding or resistance to killing of N. meningitidis by NHS. fH binding and resistance to killing by NHS were determined for isogenic lptA mutants of unencapsulated (cap−) H44/76. (A) Serum bactericidal assays were performed on H44/76 cap− and its isogenic lptA mutant, using 2.5% NHS (2.5% NHS is capable of killing N. meningitidis [see Fig. 7]). Values represent the mean (± range) survival in NHS, calculated from three or more separately performed experiments. (B) fH binding to isogenic lptA mutants of N. meningitidis. Meningococci were incubated with purified human fH (5 μg/ml), and bound ligand was detected using anti-fH MAb 90X and anti-mouse IgG–FITC. A mutant that also lacked fHbp (H44/76 cap− fHbp lptA::spc) was included as a negative control. A representative control where fH was omitted from the reaction mixture is shown (shaded gray). Each experiment was repeated at least three times.
ably correlated with the ability to resist killing by NHS. Strains sialylated. On the other hand, strains FA1090 lptA::spc, were readily killed by NHS, even when they were sialylated. Binding of fH to sialylated FA1090 lptA::spc promoted resistance to killing by 10% NHS, while binding of fH to sialylated FA1090 lptA::spc did not. Resistance of gonococci to killing by NHS is a balance between activation and regulation of the complement system. The strain background dictates the ability of a specific strain to activate and also to subvert complement-mediated killing by NHS. Gonococcal strains that resist killing by NHS may bind only C4BP, only fH, or both (14, 17). Strains such as FA1090 may require both C4BP and fH to offset complement activation, while strains like 273 may prevent killing by NHS with either C4BP or fH alone. A possible explanation for the ability of NHS to kill sialylated FA1090 lptA::spc may be the presence of kinetically overwhelming classical pathway activation (the lptA::spc mutant does not bind C4BP) that can over-ride regulation by the alternative pathway (binding of fH). As an example, expression of a terminal GalNAc distal to the LNT structure of the HepI chain of LOS is a variable that results in increased killing by NHS; GalNAc expression is under the control of the phase-variable gene lgtD (47). Differences in serum sensitivity of sialylated derivatives of FA1090 lptA::spc and 273 lptA::spc may result from subtle alterations in LOS structure (i.e., LOS micro-heterogeneity). This may include, for example, the amount of terminal GalNAc (lgtD gene product) expressed, which could account for the serum sensitivity of certain strains, such as FA1090 (16, 47), but not others, such as 273 lptA::spc. Killing of Neisseria by complement is driven by a number of factors in addition to binding to C4BP and fH, and understanding the differences between sialylated lptA mutants of FA1090 and 273 will require additional studies.

LOs is an important and wide-reaching determinant of neisserial pathogenesis that plays a primary role in modulating immune defenses. Understanding the impact of structural variations of LOS on innate immune responses increases our understanding of
pathogenesis and the host immune response to Neisseria. Specifically, phosphoryl substitutions of the lipid A component of LOS, including substitution(s) involving PEA, may play a major role in the bioactivity and pathogenesis of LOS (19–22, 48, 49). Jarvis et al. recently reported a positive correlation between the level of phosphorylation of lipid A and induction of the TLR4–MD-2 pathway; greater amounts of phosphoryl substitutions on nisserial lipid A were correlated with a greater ability to induce innate immunity through activation of NF-κB (20). Preliminary studies indicate that the presence of PEA on lipid A increases the in vivo competitive fitness of gonococci in a murine model of lower genital tract infection (R. Packiam and A. Jerse, personal communication). Hence, substitutions of lipid A involving PEA likely contribute to the capacity of gonococci to resist innate host defenses during infection and may help to dictate overall fitness in vivo. Our studies demonstrate that the composition of the lipid A moiety, specifically the presence or absence of PEA, can also modulate binding of the complement regulators C4B and iF to gonococci. Understanding the impact of LOS variation upon nisserial pathogenesis will increase our understanding of the pathogenesis and immune response to these organisms.

ACKNOWLEDGMENTS

This work was supported by NIH grants AI32725 and AI08408 to P.A.R. and AI054544 to S.R. and by a VA merit award to W.M.S. W.M.S. is the recipient of a Senior Research Career Scientist Award from the Department of Veterans Affairs Medical Research Service and is also supported in part by NIH grant U19 AI301496 (to P.F. Sparling, University of North Carolina-Chapel Hill).

REFERENCES


